anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention concerns the use of isolated secreted vesicles produced by enriched renal cell populations for providing a regenerative effected to a kidney.  Specifically, the vesicles may comprise exosomes that comprise a microRNA, and the microRNA rnay inhibit signaling of one or more of Plasminogen Activation Inhibitor-1, Transforming Growth Factor Beta or Nuclear Factor Kappa Beta.  The regenerative effect may be a reduction in renal fibrosis or inflammation.  Provided herein are also methods of assessing whether a kidney disease patient is responsive to treatment with a therapeutic comprising a population of renal cells enriched for tubular cells. The methods include a step of detecting the amount of a marker associated with vesicles in a test urine sample of a patient treated with the therapeutic relative to the amount of the marker associated with the vesicles in a control urine sample. In the method, a higher or lower amount of the marker associated with the vesicles in the control sample compared to the test sample is an indication of thc patient's responsiveness to the therapeutic.
Participants received pioglitazone in a 16 week run-in period (30 mg per day orally for 8 weeks followed by 45 mg per day orally for 8 weeks). Participants then received piogliatzone 45 mg daily orally plus 18 μg of Peginterferon Alfa-2a (PEG-INF alpha-2a) subcutaneous (sc) once a week plus ribavirin (1000 - 1600 mg/day orally as a split dose in the morning and the evening based on the participant's body weight) for 48 weeks in the anti-HCV treatment phase. Participants received 45 mg of pioglitazone per day orally in the 24 week follow-up period.
The present invention discloses a capsule for curing diabetes and a preparation process thereof. Pachyrhizua angulatus, trichosanthes root, liquorice, rehmannia root are taken and pulverized into fine powder for standby. Unprocessed rehmannia root, ophiopogon japonicus and silkworm are decocted in water. Decocted liquid is collected, filtered and concentrated; clear paste and the fine powder are uniformly mixed to be made into granules which are dried, sieved and encapsulated. The present invention has the advantages of good therapeutic effect, no toxic side effect, convenient administration, low price, etc. and has the efficiency of nourishing blood, nourishing Yin, clearing heat to reduce pathogenic fire, benifiting stomachs, promoting fluid, nourishing livers and lungs, relieving restlessness and quenching thirst.
The goal of this clinical trial (pilot study) is to evaluate the Efficacy and Safety of Combined Hyaluronic Acid and Dexamethasone Treatment in Patients with Hearing Loss. The main questions it aims to answer are: • Q1. Verification of safety, • Q2. Therapeutic effect of drug injection on sensorineural hearing loss. Participants will undergo several assessment tests (Verification of adverse effects in the external and middle ear through endoscopy, Confirmation of adverse effects through imaging, Hearing test to check for additional hearing loss, Check if subjective ear fullness persists for more than a week aside from the drug effect). If there is a comparison group: Researchers will compare dexamethasone and hyaluronic acid to verify hearing improvement and safety.
The CIPI Study is 16-week program that combines Conditional Cash Transfer (CCT) and group-based supportive After Care (AC) for moderate and high risk FESW ATS users using a stepped wedge randomized cluster design. The trial tests the CCT+AC intervention in 10 Cambodian provinces (clusters). Outcome Evaluation (OE) data is collected at 1 time-point prior to implementation of the CCT+AC program (Baseline), and 3 time-points after the intervention (OE-1, OE-2, and Post-OE) at 6, 12, and 18 months after baseline in each province. CCT+AC is followed by a linked economic capacity building opportunity. Women who are ATS-free, including those negative at baseline and those who successfully complete the CCT+AC intervention are eligible for referral to a MicroEnterprise (ME) program. The ME program combines financial literacy education and referral to a Cambodian registered microfinance organization (Chamroeun) for loan applications that may support alternate economic options for participating eligible women.
PURPOSE:To obtain the titled safe, industrially and efficiently producible pharmaceutical, having improved residence time in the stomach and quantitatively containing a drug, by coating a core consisting of a fat and oil with at least one layer of film and blending the drug in at least one layer of the above- mentioned film. CONSTITUTION:An intragastric floating pharmaceutical obtained by coating a core consisting of a fat and oil having <=0.98, preferably <=0.95 specific gravity, such as a vegetable oil, e.g. sesame oil or olive oil, animal oil, such as squalene or liver oil, or medium fatty acid triglyceride with at least one layer of film and blending a drug desired to directly sustain drug effects in the stomach, drug having absorption sites limited in the superior part of the small intestine and desired sustained absorption, etc., in at least one layer of the film. At least one of the above-mentioned film is preferably consists of a film base material containing 30-70wt.% agar. When the agar film is provided just on the core, sustained release properties are exhibited. When the film is provided in the outermost layer, irritancy and mucosal irritancy are reduced with hardly any adhesive properties to the stomach or intestinal wall.
Diagnosed adenomatous medium risk polyps after histopathological analysis of biopsy and polypectomy pieces taken within a colonoscopy. With 5 to 9 non-advanced serrated adenomas or polyps and/or at least 1 advanced lesion (adenoma \>10mm and/or hairy component and/or high-grade dysplasia or serrated polyp \>10mm and/or dysplasia).
PURPOSE:To obtain two kinds of alpha1-AG compound useful as antitumor agent, by administering a mammal with antitumor lichen polysaccharide to produce a large amount of acidic glycoprotein alpha1-AG in body liquid, and separating and purifying the compound. CONSTITUTION:A mammal, preferably a mammal affected with ascites carcino ma is administered with antitumor lichen polysaccharide (abbreviated as ALP) to produce a large amount of 'alpha-AG in ascites, and two kinds of alpha1-AG compounds, i.e. alpha1-AG-1 and alpha1-AG-2 are separated and purified by a combina tion of conventional separation and purification processes. Fractional isoelectric electrophoresis is most effective as the final purification means. The isoelectric point of alpha1-AG-1 is 3.2 and that of alpha1-AG-2 is 3.4 on a Model 1404 electrophore sis cell of Bio-Rad Inc. using Ampholin pH2.5-4.5R. The alpha1-AG of mouse exhibits strong antitumor activity against leukemia cell L-1210, Sarcoma 180, etc. The alpha1-AG-1 has an antitumor activity of about 10 times as high as that of the alpha1-AG-2.
Stress urinary incontinence (SUI) is defined as a condition characterized by the involuntary leakage of urine during activities that increase intra-abdominal pressure which may decrease quality of life with a significant economic impact on health systems, necessitating the implementation of cost-effective management plans. Urodynamics (UDS) has been considered during the last decades as the gold standard for assessment of lower urinary tract symptoms (LUTS) due to their high reproducibility. At the same time, concerns about the systematic use of UDS before SUI surgery were raised due to a limited evidenced base to recommend their routine use. In uncomplicated female patients with SUI, UDS can offer further insights into LUTS, potentially assisting the physician in determining the appropriate therapeutic approach. However, it has not been shown that preoperative UDS can directly impact the surgical outcome for continence. Indeed, evidence supports the conclusion that pre-operative UDS in women with uncomplicated, clinically demonstrable, SUI does not improve the outcome of surgery for SUI. Nevertheless, asymptomatic detrusor overactivity (DO) identified by urodynamic testing or pre-existing voiding dysfunction are associated with an increased occurrence of postoperative overactive bladder (OAB) and voiding dysfunction, respectively. The EUGA Working Group concluded that the evidence does not support the systematic preoperative use of UDS for uncomplicated cases. However, in cases where mixed symptoms, voiding dysfunction, previous surgery, or concomitant prolapse are present, preoperative UDS are advised as they can be beneficial in anticipating postoperative outcomes. This aids in conducting comprehensive and thorough preoperative counseling. The Group recommend performing preoperative UDS considering the patient's specific clinical situation and the surgeon's judgment, with consideration given to the potential benefits, risks, and impact on treatment decisions and patient outcomes.
How do we help those problem drinkers who will never seek treatment? This is a challenging issue because of the large number of problem drinkers and the limited amount of resources available. Public health initiatives employing educational materials have met with little or no success. However, clinical research has developed effective brief interventions to help problem drinkers. This project will merge these two worlds, modifying a clinically developed intervention and producing it in an ultra-brief format that is suitable for use as a public health intervention. The major objective of this proposal is to conduct a randomized controlled trial of an ultra-brief, personalized feedback intervention for problem drinkers. The advantages of the personalized feedback pamphlet are that it is low cost and can be widely distributed to the population of problem drinkers who never seek treatment. Because the materials are based on some of the best of research-based interventions, such an ultra-brief normative feedback pamphlet has the potential of helping problem drinkers. An effective intervention of this type would yield significant public health benefit. 1830 problem drinkers will be recruited on a baseline population telephone survey and randomized to one of three conditions - personalized feedback pamphlet condition, control pamphlet condition (to test if it is the specific content of the pamphlet that leads to the change or just the receipt of any pamphlet) and a no intervention control condition (sent intervention pamphlet after the six-month follow-up). In the week after the baseline survey, all households in the postal code areas that contain respondents in the two pamphlet conditions will be sent their respective pamphlets. Changes in drinking will be assessed on post intervention three-month and six-month follow-ups. Drinking outcomes will be compared between experimental conditions. The primary hypothesis is that respondents from households who receive the personalized feedback pamphlet intervention will display significantly improved drinking outcomes at three and six-month follow-ups as compared to respondents from households in the no intervention control condition. Secondary hypotheses will test the impact of the intervention on help seeking, and explore the mediating or moderating role of perceived drinking norms, perceived risk and the problem drinker's social reasons for drinking.
The present invention provides, as an artificial nucleic acid antisense antineoplastic agent capable of exhibiting an effect on a broad range of types of malignant tumor in vivo, irrespective of the delivery device, an oligonucleotide which has a base length of 13-17, which includes at least an 8-base-length moiety of the sequence represented by SEQ. ID NO.: 1 or SEQ. ID NO.: 2, and which regulates expression of YB-1. The oligonucleotide preferably comprises the sequence represented by SEQ. ID NO.: 2, is provided with a sugar moiety crosslinked-type nucleoside structure, and has phosphorothioate-type internucleotide linkages.
Women of the required age group, in case of suspicion of breast cancer, are sent to clarify the diagnosis for mammography or ultrasound of the mammary glands, or MRI. Based on the results of these studies, a biopsy is prescribed to make a final diagnosis. Before a biopsy to diagnose the presence / absence of breast cancer, patients do the blood sampling one time. The blood is processed in the Sponsor's laboratory. The test results are compared with the data obtained from the biopsy. The evaluation of the effectiveness of the method will be determined on the basis of the obtained data on the sensitivity and specificity of the test in relation to the reference method.
Over 33 million U.S. women will transition through menopause in the next decade. Among women with natural menopause, the transition typically lasts four years, with a mean age at menopause of 51 years. Menstrual irregularity (90%) and vasomotor symptoms (VMS) (80%) are the most common symptoms associated with the transition. Hormone therapy has been the gold standard for treating VMS symptoms against which other therapies are measured. However, resistance to hormone therapy use due to its risks and side effects continues to fuel the search for safer alternatives.

This research study will evaluate three low risk interventions (yoga, exercise, and omega-3 supplements) compared to either a usual activity group or a placebo pill. This factorial design is motivated by the desire to have all women receive some intervention. Neither comparisons between yoga and exercise nor tests of interaction between the behavioral interventions (yoga, exercise, usual activity) and omega-3 motivated this design. However, these aspects can be examined in secondary analyses in a more rigorous fashion through this design than would be permitted by separate trials.
Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 4 week prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily for the next 3 weeks pre-TQD and until 11 weeks post-TQD. Participants randomized to this intervention will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
In this study, the impact of culture media filtrate of QD3 actinobacterial isolate on two potato cultivars, Spunta and Diamond, infected with potato virus Y (PVY) was investigated. Various parameters, including infection percentage, PVY virus infectivity, disease severity scoring, PVY optical density, photosynthetic and defense-related biochemical markers, enzymatic profiling, phenolic compounds, proline content, salicylic acid levels, and growth and yield parameters, were assessed to elucidate the potential of the QD3 actinobacterial isolate culture filtrate in mitigating PVY-induced damage. The physiological and biochemical characteristics of the QD3 actinobacterial isolate, including its salinity tolerance, pH preferences, and metabolic traits, were investigated. Molecular identification via 16S rRNA gene sequencing confirmed its classification as Streptomyces fradiae QD3, and it was deposited in GenBank with the gene accession number MN160630. Distinct responses between Spunta and Diamond cultivars, with Spunta displaying greater resistance to PVY infection. Notably, pre-infection foliar application of the QD3 filtrate significantly reduced disease symptoms and virus infection in both cultivars. For post-PVY infection, the QD3 filtrate effectively mitigated disease severity and the PVY optical density. Furthermore, the QD3 filtrate positively influenced photosynthetic pigments, enzymatic antioxidant activities, and key biochemical components associated with plant defense mechanisms. Gas chromatography‒mass spectrometry (GC‒MS) analysis revealed palmitic acid (hexadecanoic acid, methyl ester) and oleic acid (9-octadecanoic acid, methyl ester) as the most prominent compounds, with retention times of 23.23 min and 26.41 min, representing 53.27% and 23.25%, respectively, of the total peak area as primary unsaturated fatty acids and demonstrating antiviral effects against plant viruses. Cytotoxicity assays on normal human skin fibroblasts (HSFs) revealed the safety of QD3 metabolites, with low discernible toxicity at high concentrations, reinforcing their potential as safe and effective interventions. The phytotoxicity results indicate that all the seeds presented high germination rates of approximately 95-98%, suggesting that the treatment conditions had no phytotoxic effect on the Brassica oleracea (broccoli) seeds, Lactuca sativa (lettuce) seeds, and Eruca sativa (arugula or rocket) seeds. Overall, the results of this study suggest that the S. fradiae filtrate has promising anti-PVY properties, influencing various physiological, biochemical, and molecular aspects in potato cultivars. These findings provide valuable insights into potential strategies for managing PVY infections in potato crops, emphasizing the importance of Streptomyces-derived interventions in enhancing plant health and crop protection.
1358734 Concentrating &c influenza virus SOUTH AFRICAN INVENTIONS DEVELOPMENT CORP 16 Aug 1971 [14 Aug 1970 30 Dec 1970] 38317/71 Heading A5B Influenza virus is obtained in a concentrated and purified form from an aqueous suspension thereof by adding to the suspension up to 5% by weight of polyethylene glycol (PEG) of M.W. 3000 to 20000 or an equivalent linear, filamentary, uncharged water-soluble polymer such as dextran, other polyalkylene glycols, poly 1, 4-dihydroxy butane glycol, nonylphenol-ethoxylate, polyvinyl alcohol or polyvinyl pyrrolidone and separating the insolubilized material. Under certain conditions, the virus is obtained in a dense, "intimately aggregated"- form in which the virus is in strongly coherent clusters in which individual particles may be disrupted, e.g. to release nucleic acids, without disruption of the aggregate. In a modification of the process, PEG is added up to 1% by weight and the resultant is subjected to phase separation to separate a protein-rich and protein-poor phase. The former is separated and the residual matter is treated with further PEG to a concentration at least 1% higher to produce another protein-rich fraction, either the protein-rich or protein-poor material being useful. The purified virus may be used for making vaccines.
Intervention 2: Peripherals with HealthInterlink technology will record and transmit data and send out-of-range data (Red) alerts to subject via HealthInterlink tablet/smartphone and also text/email to family/other caregiver, and nonconformity (Blue) alerts to subject's personal text/email and also text/email to family/other caregiver, and a call will be placed by the nurse research assistant to study subject (on Blue alerts) or study subject's healthcare professional (on Red alerts). The physicians will have access to the subject's data on a web-based program.
The investigators plan to randomize 60 out of 120 infants to be weaned to a cow's milk based infant formula. Recruited mothers are encouraged to breast-feed. The dietary intervention will be applied until 9 months of age. The minimum exposure time to the study formula should be 90 days. Signs of beta-cell autoimmunity, i.e. diabetes-associated autoantibodies, will be monitored in the study participants, although the study will not have sufficient power to detect statistically significant differences in the seroconversion rate between the groups due to the limited number of infants randomized.
Impaired Liver Function   


Do not use Tri-Lo-Mili in women with liver disease, such as acute viral hepatitis or severe (decompensated) cirrhosis of liver [see Contraindications (4)]. Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal and COC causation has been excluded. Discontinue Tri-Lo-Mili if jaundice develops.

Liver Tumors   


Tri-Lo-Mili is contraindicated in women with benign and malignant liver tumors [see Contraindications (4)]. Hepatic adenomas are associated with COC use. An estimate of the attributable risk is 3.3 cases/100,000 COC users. Rupture of hepatic adenomas may cause death through intra-abdominal hemorrhage.

Studies have shown an increased risk of developing hepatocellular carcinoma in long-term (>8 years) COC users. However, the risk of liver cancers in COC users is less than one case per million users.
PURPOSE:To provide a new diuretic peptide for diuretic agents, hypotensive agents, vasodepressors etc., obtainable from the shark's auricle, ventricle or brain, having such structure that amino acids are not bound toward the C-terminal from the cysteine on the C-terminal side of the basic skeleton. CONSTITUTION:The auricle, ventricle and brain are taken out from sharks and boiled in distilled water for 5min and then cooled; acetic acid is then added to the system followed by homogenization with a mixer to effect extraction, and the extract liquor is centrifugalized to collect the supernatant. This supernatant is then brought to dryness under reduced pressure and the resulting residue is dissolved in 1M acetic acid followed by addition of acetone and then centrifugation. The resultant sedimented residue is dissolved in 1M acetic acid again followed by gel filtration to collect a fraction with chicken rectum preparation relaxative activity, which is, in turn, put to cation exchange high-performance liquid chromatography and reversed-phase high-performance liquid chromatography, successively, to effect purification, thus obtaining the objective diuretic peptide of e.g. formula I (X is H, the entire sequence of formulae, etc.) having such structure that amino acids are not bound toward the C-terminal from the cysteine on the C-terminal side of the basic skeleton made up of 17 amino acids.
In order to produce glossy pigments based on platelike silicate substrates provided with several coatings, the substrates already coated with a first layer of colourless or selectively absorbing metal oxide are (a) at first coated with a second, non-selectively absorbing layer essentially composed of carbon, metal and/or metal oxide, and then (b) are coated, if required, with a third layer of colourless or selectively absorbing metal oxide. The carbon layer (step a) is applied by thermal decomposition of oxygenated hydrocarbons which contain at least one oxygen atom for each pair of carbon atoms. The metal layer (step a) is applied by gas phase decomposition of volatile compounds of said metals in an inert gas. The metal oxide layer (steps a and/or b) is applied by gas phase decomposition of volatile compounds of said metals in the presence of oxygen, steam or mixtures thereof. In case (a), said layers are applied on substrates already coated with a first metal oxide layer and in case (b), said layers are applied on substrates coated with a second, non-selectively absorbing layer (a). Also disclosed are special pigments, the production and use of such glossy pigments for colouring lacquers, printing inks, plastics, decorative cosmetic compositions, glass and ceramic products.